Cell Medica announces the appointment of Kevin Boyle as Chief Financial Officer

Cell Medica announces the appointment of Kevin Boyle as Chief Financial Officer to head up the Company’s international financial activities

 

Cell Medica, a leader in cellular immunotherapy for the treatment of cancer, announced today the appointment of Kevin S. Boyle, Sr. as Chief Financial Officer, based in Houston, TX. With over 20 years of financial and capital markets experience, Kevin joins the senior executive team as the company prepares for ground-breaking clinical trials to investigate cancer treatments utilizing Cell Medica’s innovative chimeric antibody receptor (CAR) and engineered T cell receptor (TCR) cell therapies.

Kevin has held senior finance roles at both NASDAQ-listed and private equity backed companies. He is an accomplished capital markets professional with strong banking relationships cultivated by raising over $2.0 billion in equity and debt capital. At Cell Medica, Kevin will play a lead role in both corporate strategy and financial planning as the Company progresses with an exciting pipeline of CAR and TCR products in both the US and Europe. Kevin received a law degree from the University of Pennsylvania and a Bachelor of Science degree in Industrial Management & Economics from Carnegie Mellon University.

Gregg Sando, CEO Cell Medica, commented:

“We look forward to Kevin joining Cell Medica as we prepare for significant growth in our CAR and TCR development activities. His US capital markets experience and proven deal-making acumen will complement the capabilities of our current senior management team and help us realise the immense potential of our cell-based immunotherapies for the treatment of cancer patients.”

Kevin Boyle, Cell Medica’s Chief Financial Officer, added:

“I am excited to join the Cell Medica team as it is poised to enter the clinical phase with new technologies for treating cancer. I look forward to helping the company achieve its goals by accessing the capital markets to fund a robust R&D pipeline.”